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Background: Studies adopting electronic medical records and genomic information are becoming widespread.
Through this new modality in research, it is possible to study how genetic variants influence susceptibility towards
chronic conditions and can improve patient care.
Our aim is to develop a biobank with 2,000 heart failure patients treated in a tertiary cardiology hospital containing
electronic medical records data and biologic samples for performing genome-wide association studies for validation
and development of medical decision routines aimed at helping the clinical management of patients.
Methods/Design: Patients between 18 and 80 years old with heart failure diagnosis of different etiologies and left
ventricular ejection fraction ≤ 50% in the past 2 years will be eligible for enrollment on the cohort. After consent,
patients will be submitted to clinical baseline, echocardiography, cardiograph impedance and biochemical
evaluation. Study data will be collected and managed using Research Electronic Data Capture tools. The follow up
will take place every 6 months to assess cardiovascular outcomes (all-cause mortality, cardiovascular mortality,
hospitalization for worsening heart failure and current medication use). Initial analytical strategy will focus on the
establishment of the accuracy of electronic medical records extraction protocols for main predictor factors of
morbidity and mortality in heart failure.
Discussion: Building a biobank with biologic samples and clinical data of 2,000 heart failure patients we will
perform genome-wide association studies. By this way, we pretend to study how genetic variants influence
susceptibility towards chronic conditions. Besides, it will be created a working group focused on the development
and implementation of algorithms for validation and application of medical routines using the electronic medical
records of the Heart Institute (InCor - HCFMUSP).
Trial registration: Current Controlled Trials NTC02043431.
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Heart failure is an important cause of morbidity and
mortality worldwide and in Latin America, the risk factors
and epidemiology have peculiarities that are still unclear.
Recently, Bocchi et cols discussed the similarities in risk
factors compared to developed countries highlighting the
prevalence of others causes like Chagas’disease, rheumatic
fever and lower total expenditure on health per capita [1].
The mapping of the human genome has enabled new
exploration on how genetic variation contributes to health
and disease [2]. Technological advances in the under-
standing of disease processes are presented as new oppor-
tunities to improve healthcare through management of
individual patients. In this context, the adoption of elec-
tronic medical records (EMR), used by clinicians to docu-
ment clinical care, is becoming widespread and recent
studies demonstrate that they can be effectively employed
for genetic studies using the informational and biological
‘by-products’ of healthcare delivery while maintaining pa-
tient privacy [3].
This new approach in research leads on the Personalized
Medicine Research Project, a population-based biobank
that involves discussions about community consultation
and other legal aspects [4]. Actually, efforts to improve pa-
tients’ understanding of their own medical treatments or
research in which they are involved are progressing, espe-
cially with regard to informed consent procedures [5].
Recently, the National Human Genome Research In-
stitute (NHGRI) called on researchers to determine how
genetic variants influence susceptibility towards chronic
conditions such as diabetes, Alzheimer’s disease, and car-
diovascular disease, in order to ultimately improve patient
care. For this purpose, the eMERGE (electronic MEdical
Records and GEnomics) Network – an NHGRI-supported
consortium of five institutions – was created to explore
the utility of DNA repositories coupled to EMR systems
for advancing discovery in genome science [6].
Allied to this new modality in research, the adoption
of an online database allows easy access and processing
of information collected in a safe and efficient way. The
Research electronic data capture (REDCap) is a novel
workflow methodology and software solution designed
for rapid development and deployment of electronic data
capture tools to support clinical and translational research.
It was initially developed and deployed at Vanderbilt Uni-
versity, but now has collaborative support from a wide
consortium of domestic and international partners [7].
It is clear that new strategies are essential for preven-
tion and treatment of chronic diseases like heart failure.
Conditions described in Latin America that has peculiar
epidemiology compared to other countries, need further
studies. In this scenario, our aim is to develop a biobank
containing samples of 2,000 patients with heart failure diag-
nosis treated in a tertiary cardiology hospital containingelectronic medical record and genetic data in genome-wide
scale for performing genetic association studies for valid-
ation and development of medical decision routines that
help the clinical management of these patients.
Methods/Design
Research design
Subjects with systolic heart failure, sequentially included,
will be submitted to clinical baseline, echocardiography,
cardiograph impedance and biochemical evaluation, which
include blood, urine and exhaled breath acetone samples.
It will allow the authors to best define the heart failure
syndrome, its etiology and its hemodynamic profile. All
patients included will also be submitted to clinical
follow-up every 6-month for 3 years to assess cardio-
vascular outcomes: all-cause mortality, cardiovascular
mortality, hospitalization for worsening heart failure,
current medication use and heart transplantation. The
diagnosis of heart failure will be made according to pre-
viously published criteria [8]. To define the appropriate
etiology of cardiomyopathy, the authors will follow pre-
vious guidelines [9,10].
Patients selection
The individuals invited to our study will be consecutively
selected from the Heart Institute - Clinical Hospital- Uni-
versity of São Paulo Medical School (InCor - HCFMUSP)
on their outpatient admission, starting at January 2011.
Ethics
The study protocol was approved by the Ethics Commit-
tee for Medical Research on Human Beings of the Clinical
Hospital from University of São Paulo Medical School
(SDC 2368/03/162). Signed informed consent will be ob-
tained from all participants.
Inclusion criteria
Patients between 18 and 80 years old with heart failure
diagnosis of different etiologies and left ventricular ejec-
tion fraction ≤ 50% on two-dimensional transthoracic
Doppler echocardiography performed in the past 2 years,
who are admitted to the Heart Institute from January
2011, will be eligible for enrollment on the cohort. Spe-
cifically, patients with cardiomyopathy due to valvular
heart disease enrolled in the study will be those with se-
vere left ventricular dysfunction to the point that they
would not be eligible for valve repair or replacement,
but rather candidates for heart transplantation.
Exclusion criteria
Patients with impaired cognition due to advanced de-
mentia syndrome or severe psychiatric disorder, without
telephone access or that refuse to participate will be
excluded.
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During echocardiography, transthoracic images will be
obtained with the patient in the left lateral position using
Acuson Sequoia 512 (Siemens). The image acquisitions
will be standardized in the four windows: parasternal
long and short axis, and apical 4 - and 2-chambers. The
evaluation of the left ventricular (LV) function will be
performed by the echocardiography staff in a blinded
way in relation to the protocol and will be conducted ac-
cording to previously standard recommendations. Left
ventricular systolic and diastolic volumes and ejection
fraction will be derived from biplane apical views using
the modified Simpson’s rule algorithm. Diastolic dys-
function will be determined using Doppler measure-
ments of mitral inflow and Doppler tissue imaging (DTI)
of the mitral annulus.
Biobanking
All enrolled patients will have fasting serum, exhaled
breath acetone, plasma and urine samples collected and
stored at -80°C for further analysis.
Genomic DNA protocol
Genomic DNA will be extracted from peripheral leuco-
cytes after a standard salting out protocol [11]. DNA
quality and integrity will be checked in all samples after
extraction protocol.
Whole-blood RNA collection
The enrolled patients will have whole-blood RNA col-
lected in fasting state and stored in PAXGene tubes for
further analysis according to standard protocol [12].
Exhaled breath acetone (EBA)
The exhaled breath acetone has been described as a good
biomarker of the diagnosis of heart failure as previously
described [13] and will be used associated to BNP (B-type
natriuretic peptide) and clinical criteria. After collection of
blood samples, patients will have standard diet and will be
submitted to the exhaled breath acetone collection by
using a simple and portable device. After collection, the
liquid phase of the sample will be transferred from the
device to a capped vial and stored in a freezer at -80°C
until acetone analysis.
Studied variables
Enrolled patients will have the opportunity to contribute
to genetic associations regarding a number of demo-
graphic, clinical and follow-up information. All included
individuals will have data on sex, ethnicity, age, duration
of symptoms, etiology of heart failure, history of diabetes
mellitus, arterial hypertension, smoking, drugs and mor-
bidity outcomes. Anthropometric data like body mass
index, heart rate, blood pressure, cardiac rhythm, cardiacdimensions on echocardiography and left ventricle ejec-
tion fraction (both baseline and sequential in one year
intervals). We will perform serum analyses (sodium, po-
tassium, total cholesterol, triglycerides, HDL-cholesterol,
LDL-cholesterol, VLDL-cholesterol, glucose, creatinine,
urea, B-type natriuretic peptide), exhaled breath acetone
dosage and urine analyze. Follow-up will be assessed
every 6 months to investigate clinical outcomes as cited
above. In addition, the mortality database of São Paulo
City Authority will also be periodically scrutinized to
discover patient deaths (ProAim-Programa de Aprimor-
amento de Informações de Mortalidade do Municipio de
São Paulo). Follow-up will be carried for all individuals
until a 3-year period.
Electronic data collection (REDCap)
Study data will be collected and managed using REDCap
electronic data capture tools hosted at the Clinical Hos-
pital from University of São Paulo Medical School. RED-
Cap (Research Electronic Data Capture) is a secure, web-
based application designed to support data capture for
research studies, providing: 1) an intuitive interface for
validated data entry; 2) audit trails for tracking data ma-
nipulation and export procedures; 3) automated export
procedures for seamless data downloads to common stat-
istical packages; and 4) procedures for importing data
from external sources [7].
Cardiograph impedance
Hemodynamic data will be obtained noninvasively using
a monitor CardioScreen 2000 (Medis, Germany) approved
for marketing by U.S. Food and Drug Administration
(FDA). This device measures the thoracic bioimpedance
using the following technique: four dual sensors (each sen-
sor consists of two electrodes) are placed on the patient,
on opposite sides of the neck, at a level between the ears
and shoulders and on both sides of the chest in the
mid-axillary line at the level of the xiphoid process. The
electrodes transmit a current of low amplitude and high
frequency (2.5 mA and 70 kHz), and detect changes in
voltage chest. These alterations in voltage are used to
calculate the impedance (Z). The following parameters
will be assessed: Cardiac index (CI), Stroke Volume
Indexed (SVI), Mean Arterial Pressure (MAP), systemic
vascular resistance index (SVRI), Thoracic Fluid Con-
tent Indexed (CLTI), velocity index, acceleration index,
pre-ejection period, LV ejection time, and systolic time
ratio (inversely proportional to LV function; pre-ejection
period divided by LV ejection time).
Genome-wide association studies (GWAS)
The genomic DNA samples will be processed and geno-
typed in the Affymetrix biobank platform for around
800.000 polymorphic markers. For quality control, will
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of the samples, SNPs with allele frequency rarer (MAF)
<1%, or results to Hardy-Weinberg test <0.001. Further,
after exclusion of SNPs with quality problems in geno-
typing, individuals will be analyzed for consistency of
genotyping. Individuals with genotyping rate <90% will
be excluded.Development of diagnostic algorithms based on
electronic medical records
The Heart Institute (InCor - HCFMUSP) had developed
and used an in-house system of electronic medical re-
cords in the last 2 decades. This information system has
medical data that need to be validated for use in system-
atic clinical research. Using these medical records we
pretend to create algorithms for data extraction that en-
able selection and classification of individuals, or the
extraction of continuous variables of medical interest
that can be used in research protocols or development
of medical decision tools. In summary, we intent to
evaluate the validity and specificity of this data collection
system and apply it in genetic association studies as well
as medical routines of the Institute.Statistical analysis
Data will be analyzed using SPSS for Windows version
13.0 (SPSS Inc) statistical software.Discussion
We expect to develop a biobank containing samples and
clinical data of 2,000 patients with heart failure diagnosis
for performing genetic association studies. Besides, we
aim to create a working group focused on the develop-
ment and implementation of algorithms for validation
and application of medical decision routines using our
electronic medical record system in order to help the
clinical management of patients at the Heart Institute
(InCor - HCFMUSP). Furthermore, the project will focus
on ethical, legal, political and social impact of this new
reality, such as privacy, confidentiality and possible in-
teractions with the community. In this sense, we intend
to identify sources of concern among participants re-
garding current approaches to obtaining informed con-
sent for storage and use of genetic material in clinical
research.
In this way, with the appropriate use of genetic data in
genome-wide scale associated to electronic medical in-
formation, we expect to accelerate both the discovery of
genetic factors associated with complex diseases such as
heart failure and create medical decision routines that
help the clinical management of patients in a tertiary
cardiology hospital.Abbreviations
EMR: Electronic medical records; NHGRI: National Human Genome Research
Institute; eMERGE: electronic MEdical records and GEnomics;
REDCap: Research electronic data capture; LV: Left ventricular; DTI: Doppler
tissue imaging; EBA: Exhaled breath acetone; BNP: B-type natriuretic peptide;
FDA: Food and Drug Administration; Z: Impedance; CI: Cardiac index;
SVI: Stroke volume indexed; MAP: Mean arterial pressure; SVRI: Systemic
vascular resistance index; TFCI: Thoracic fluid content indexed;
GWAS: Genome-Wide Association Studies.
Competing interests
The authors declare that they have no potential conflicts of interest
regarding the present publication.
Authors’ contributions
LGP performed the acquisition of data, drafted the manuscript. SBP
performed the acquisition of data, helped to draft the manuscript. FGMB
performed the acquisition of data, helped to draft the manuscript. JMRS
performed the collection of data, carried out part of the molecular genetic
studies. RMMS performed the collection of data. NEF carried out part of the
molecular genetic studies. FB helped in the patients recruitment. FF helped
in the patients recruitment. AJM participated in study design and helped in
the patients recruitment. JEK conceived the study, and participated in its
design. ACP conceived of the study, and participated in its design and
coordination and helped to draft the manuscript. All authors read and
approved the final manuscript.
Acknowledgments
Samaritan Hospital of São Paulo and Brazilian Ministry of Health - Programa
de Apoio ao Desenvolvimento Institucional do Sistema Único de Saúde
(PROADI-SUS) for financial support.
Author details
1Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor) of
University of São Paulo Medical School, Avenue Dr. Enéas de Carvalho
Aguiar, 44 Cerqueira César, São Paulo, SP 05403-000, Brazil. 2Heart Institute
(InCor) of University of São Paulo Medical School, São Paulo, Brazil.
3Fluminense Federal University, Niteroi, Rio de Janeiro, Brazil.
Received: 10 February 2014 Accepted: 25 February 2014
Published: 4 March 2014
References
1. Bocchi EA, Arias A, Verdejo H, Diez M, Gomez E, Castro P: The reality of
heart failure in Latin America. J Am Coll Cardiol 2013, 62(11):949–958.
2. Dries DL: Genetic ancestry, population admixture, and the genetic
epidemiology of complex disease. Circ Cardiovasc Genet 2009,
2(6):540–543.
3. Kohane IS: Using electronic health records to drive discovery in disease
genomics. Nat Rev Genet 2011, 12(6):417–428.
4. McCarty CA, Chapman-Stone D, Derfus T, Giampietro PF, Fost N: Community
consultation and communication for a population-based DNA biobank: the
Marshfield clinic personalized medicine research project. Am J Med Genet A
2008, 146A(23):3026–3033.
5. Cervo S, Rovina J, Talamini R, Perin T, Canzonieri V, De Paoli P, Steffan A:
An effective multisource informed consent procedure for research and
clinical practice: an observational study of patient understanding and
awareness of their roles as research stakeholders in a cancer biobank.
BMC Med Ethics 2013, 14:30.
6. McCarty CA, Chisholm RL, Chute CG, Kullo IJ, Jarvik GP, Larson EB, Li R,
Masys DR, Ritchie MD, Roden DM, Struewing JP, Wolf WA, eMERGE Team:
The eMERGE Network: a consortium of biorepositories linked to
electronic medical records data for conducting genomic studies. BMC
Med Genomics 2011, 4:13.
7. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG: Research
electronic data capture (REDCap)–a metadata-driven methodology and
workflow process for providing translational research informatics
support. J Biomed Inform 2009, 42(2):377–381.
8. McKee PA, Castelli WP, McNamara PM, Kannel WB: The natural history of
congestive heart failure: the Framingham study. N Engl J Med 1971,
285(26):1441–1446.
Gioli-Pereira et al. BMC Cardiovascular Disorders 2014, 14:32 Page 5 of 5
http://www.biomedcentral.com/1471-2261/14/329. Bocchi EA, Marcondes-Braga FG, Bacal F, Ferraz AS, Albuquerque D,
Rodrigues Dde A, Mesquita ET, Vilas-Boas F, Cruz F, Ramires F, Villacorta H Jr,
Souza Neto JD, Rossi Neto JM, Moura LZ, Beck-da-Silva L, Moreira LF, Rohde
LE, Montera MW, Simões MV, Moreira Mda C, Clausell N, Bestetti R,
Mourilhe-Rocha R, Mangini S, Rassi S, Ayub-Ferreira SM, Martins SM,
Bordignon S, Issa VS: Updating of the Brazilian guideline for chronic heart
failure - 2012. Arq Bras Cardiol 2012, 98(1 Suppl 1):1–33.
10. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K,
Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip
GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK,
Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA,
Zannad F, Zeiher A: ESC Guidelines for the diagnosis and treatment of
acute and chronic heart failure 2012: the task force for the diagnosis
and treatment of acute and chronic heart failure 2012 of the European
society of cardiology. Developed in collaboration with the Heart Failure
Association (HFA) of the ESC. Eur Heart J 2012, 33(14):1787–1847.
11. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for
extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16
(3):1215.
12. Rainen L, Oelmueller U, Jurgensen S, Wyrich R, Ballas C, Schram J, Herdman
C, Bankaitis-Davis D, Nicholls N, Trollinger D, Tryon V: Stabilization of mRNA
expression in whole blood samples. Clin Chem 2002, 48(11):1883–1890.
13. Marcondes-Braga FG, Gutz IG, Batista GL, Saldiva PH, Ayub-Ferreira SM, Issa
VS, Mangini S, Bocchi EA, Bacal F: Exhaled acetone as a new biomaker of
heart failure severity. Chest 2012, 142(2):457–466.
doi:10.1186/1471-2261-14-32
Cite this article as: Gioli-Pereira et al.: Genetic and ElectroNic medIcal
records to predict oUtcomeS in heart failure patients (GENIUS-HF) - design
and rationale. BMC Cardiovascular Disorders 2014 14:32.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
